The recent ACC/AHA guidelines recommend the use of clopidogrel for at least 1 year in ACS-PCI patients who are not at high risk of bleeding. However, use of clopidogrel may not meet this guidance due to compliance issues. In this study, 1-year compliance of clopidogrel by ACS patients with or without diabetes mellitus (DM) was studied. METHODS: A total of N 12,502 ACS patients, aged 18-64 years and hospitalized with a primary diagnosis of ACS between January 1, 2005 and December 31, 2006 were identified with complete 1-year follow-up eligibility and drug use information in the MarketScan claims database. Patients were categorized into two cohorts: DM (N 3040) and non-DM (N 9462). Adherence was measured by the medication possession ratio (MPR). Persistence was reported using the time from index hospitalization to the first gap of 30 days between exhausting the supplied medication and filling the next prescription. Adherence and persistence between cohorts was compared using propensity score-adjusted bootstrapping method. RESULTS: A total of 72.1% (2193/3040) DM patients and 76.1% (7197/9462, p 0.01) non-DM patients had at least 1 outpatient fill for clopidogrel in the 1-year after the index hospitalization. Among the clopidogrel users (64.9% PCI, 30.8% medical management, 4.3% CABG), the average MPR was 0.78 for DM patients and 0.80 for non-DM patients (p 0.189). Significantly lower persistence was observed for DM patients vs. non-DM patients (257.6 vs. 274.7 days, p 0.012). ACS patients undergoing PCI had significantly higher persistence compared to medical management patients (280.7 vs. 231.4 days, p 0.001 for DM; 285.7 vs. 254.6 days, p 0.001 for non-DM). CONCLUSIONS: Approximately three-fourths of patients in this study had used clopidogrel after being hospitalized for ACS. ACS patients with prior diabetic history were less likely to be persistent with medication than non-diabetic ACS patients. This finding might have clinical consequences since DM patients typically have higher risk of cardiac events. 6 University of Rijeka Medical School, Rijeka, Croatia OBJECTIVES: In the contemporary world, particularly in developing countries, cardiovascular (CV) diseases are a major health care problem. Agents acting on the renin-angiotensin system (RAS) have an important place in the management of these diseases. METHODS: The data concerning drugs usage prescribed by GPs during the period from 2001 to 2007 were collected from the Croatian Health Insurance Institute. Annual volumes of drugs are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data are presented in Euros (a). An average cost per DDD was calculated for this group of drugs. RESULTS: Agents acting on the RAS for the seven-year period remained the most prescribed CV drug group with the largest cost share. The use of the whole group increased 115% (from 56.07 to 120.55 DDD/1000) while the related expenses increased 53.5%. The consumption and cost shares of ACE inhibitors (plain and combined) decreased (from 98% to 88% and from 96% to 90%, respectively). The use of the combinations of ACE inhibitors and diuretics increased from 10.07 to 41.90 DDD/1000 and angiotensin receptor blockers and diuretics from 0 to 6.42 DDD/1000. The average cost per DDD for the investigated group dropped from 0.33 to 0.24 a/DDD. CONCLUSIONS: During the investigated period the usage of the group of agents acting on the RAS increased considerably. The related growth of financial expenditure increased at a slower rate. The average cost per DDD gradually decreased mainly as the result of the introduction of generics and the implementation of restrictive measures on the Croatian drug market. vs. 85.9%) were prescribed to patients with DM both in the pre-and post-index hospitalization period. While more statins (59.6% vs. 30%) and thienopyridine (14.6% vs. 6.4%) were prescribed to patients with DM in the pre-period, in the post-period statin use was similar for patients in both groups (89.1% vs. 88.0%, p 0.11) and thienopyridine use was less frequent in patients with DM (72.1% vs. 75.9%) possibly due to higher rates of CABG. CONCLUSIONS: Patients with DM had a less-favorable comorbidity profile, underwent less PCI but more CABG and were more likely to have medical management during the index hospitalization. Hospitalization with ACS shifted the usage pattern of cardiovascular medications. Interventional cardiologists collected data from ACS events to hospital discharge, and primary care physicians (PCP) and cardiologists collected follow-up data. RESULTS: A total of 483 ACS-PCI patients, median age 59 years (Q1-Q3 52-71), median weight 79 kg (Q1-Q3 70-90), 18% female, 47% with ST-elevation MI (STEMI) and 53% with unstable angina or non-ST-elevation MI (UA/NSTEMI) were recruited in France. Almost all . Almost all Almost all patients (96%) received stents: 67% bare metal stents (BMS), 23% drug eluting stents (DES) and 11% both. Median total length of hospital stay was 6 (Q1-Q3 4-8) days.
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REAL-WORLD PRACTICE PATTERNS OF ACUTE CORONARY SYNDROME (ACS) PATIENTS WITH AND WITHOUT DIABETES MELLITUS (DM)
Zhao Z 1 , Zhu B 2 , Anderson J 1 , Bayt T 2 , LeNarz L 2 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Lilly USA, LLC, Indianapolis, IN, USA OBJECTIVES: This study compared the real-world practice patterns for ACS patients with and without DM in a large privately insured population. METHODS: A retrospective cohort study was conducted using the MarketScan claims database. Patients aged 18-65 years (N 22,693) , hospitalized with a primary diagnosis of ACS between January 2005 and December 2006 were categorized into 2 groups: with DM (N 6,049) and without DM (N 16,644 vs. 85.9%) were prescribed to patients with DM both in the pre-and post-index hospitalization period. While more statins (59.6% vs. 30%) and thienopyridine (14.6% vs. 6.4%) were prescribed to patients with DM in the pre-period, in the post-period statin use was similar for patients in both groups (89.1% vs. 88.0%, p 0.11) and thienopyridine use was less frequent in patients with DM (72.1% vs. 75.9%) possibly due to higher rates of CABG. CONCLUSIONS: Patients with DM had a less-favorable comorbidity profile, underwent less PCI but more CABG and were more likely to have medical management during the index hospitalization. Hospitalization with ACS shifted the usage pattern of cardiovascular medications. . Almost all Almost all patients (96%) received stents: 67% bare metal stents (BMS), 23% drug eluting stents (DES) and 11% both. Median total length of hospital stay was 6 (Q1-Q3 4-8) days.
PCV161 HEALTH CARE RESOURCES UTILIZATION IN ACUTE CORONARY SYNDROME PATIENTS ONE YEAR AFTER PCI : FRENCH RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)
Median total length of hospital stay was 6 (Q1-Q3 4-8) days. Follow-up data on post discharge resource use up to 12 months are available for 394 (82%) patients. At discharge, these patients were receiving clopidogrel-94%, aspirin-95%, statins-82%, beta-blockers-82%, ACE inhibitors/ARBs-68%. During the year ACE inhibitors/ARBs-68%. During the year 68%. During the year following PCI, patients had on average 7.7 (SD 4.7) visits to PCPs, 3.1(SD 1.7) visits to cardiologists, and STEMI and UA/NSTEMI patients had the same number of visits to physicians. 6% of patients had planned hospital re-admissions: 8% for STEMI patients and 4% for UA/NSTEMI patients. 14% of patients had hospital re-admissions related to a cardiovascular event: 11% for STEMI patients and 16% for UA/NSTEMI patients. Mean change of EuroQol VAS between discharge and 1 year was 18.2 (SD 30.4), respectively 18.1(SD 30.0) for STEMI patients and 18.3 (SD 30.9) for UA/NSTEMI patients. CONCLUSIONS: These prospective data show that after an These prospective data show that after an ACS event, patients received a regular follow-up by primary care physicians and cardiologists. In addition, during the year following PCI, they had planned hospital re-admissions but more frequently admissions related to a cardiovascular event.
PCV162 162 PUBLIC TENDERING FOR OFF PATENT PHARMACEUTICALS IN BELGIUM-THE SIMVASTATIN CASE
VanHaeren E, Arickx F, Soete E, Bormans V, Mortier M, Leveque F RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium OBJECTIVES: To evaluate the effectiveness of a public tendering technique (so called "KIWI model") intended to lower the price of off-patent drugs and generate a sustained economy (perspective Health Insurance expenditures), applied on pharmaceuticals containing simvastatin. METHODS: In 2006, the Belgian government launched a public tender granting a preferential reimbursement level (75/85 % reimbursed versus 50 %) to the company offering the lowest price for its pharmaceuticals containing simvastatin. The economy was estimated at a14.6 million for the first year (2008 -budget for simvastatin). Health Insurance expenses were evaluated using registered financial data from NIHDI (pharmaceuticals in public pharmacies). RESULTS: In 2008, the expenses for pharmaceuticals containing simvastatin decreased with 30% versus 2007 (47 versus a32.5 million). At the same time, while in 2007 the expenses for all statins grew with 10.5% versus 2006 (a165 versus a182 million), in 2008 the expenses for all statins increased only by 6.5% versus 2007 (182 versus 193.8 mio EURO), mainly due to an increase of the expenses for atorvastatin ( 16% or a85.5 versus a99 million) and rosuvastatin ( 40% or a30 versus a42 million). CONCLU-SIONS: The substantial price reductions and the estimated economy, due to the execution of the KIWI model for simvastatin, were obtained, but counterbalanced by the growth of the expenses for other statins. A public tendering technique for off-patent molecules, intending important price reductions, is therefore considerable as a means to control Health Insurance expenditures, if shifts versus similar (on-patent) molecules (therapeutic alternatives) can be mastered.
